UK will pay for Roche breast cancer drug at center of price row

LONDON (Reuters) - A Roche breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely, following a discount deal between the company and the National Health Service, the country's cost watchdog said on Thursday.